SHZ:002082

Wanbangde Pharmaceutical Holding Group Co., Ltd. · SHZ · Healthcare · CNY · FY for 2025

Figures on this page computed 2026-11-08 13:31 UTC

Last close

n/aCNY

Market data

  • n/aP/E

    We do not hold this figure for this company, so there is nothing to place.

    Price / Earnings per Share (diluted)

    Source
    computed
    Taken on
    2026-11-08
    Reported in
    CNY
    • computed
    • Computed from the filing for 2025
  • n/aROIC

    We do not hold this figure for this company, so there is nothing to place.

    NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash

    Source
    computed
    Taken on
    2026-11-08
    Reported in
    CNY
    • Computed from the filing for 2025
    • Computed from the filing for 2025
    • Computed from the filing for 2025
    • Computed from the filing for 2025
    • Computed from the filing for 2025
    • Computed from the filing for 2025
  • n/aNet margin

    We do not hold this figure for this company, so there is nothing to place.

    Net Income / Revenue x 100

    Source
    computed
    Taken on
    2026-11-08
    Reported in
    CNY
    • Computed from the filing for 2025
    • Computed from the filing for 2025
  • n/aFCF margin

    We do not hold this figure for this company, so there is nothing to place.

    Free Cash Flow / Revenue x 100

    Source
    computed
    Taken on
    2026-11-08
    Reported in
    CNY
    • Computed from the filing for 2025
    • Computed from the filing for 2025
  • 0.32Debt/equity

    Total Debt / Shareholders' Equity

    Source
    computed
    Taken on
    2026-11-08
    Reported in
    CNY
    • Computed from the filing for 2025
    • Computed from the filing for 2025
  • 0.8%Dividend yield
    Source
    computed
    Taken on
    2026-11-08
    Reported in
    CNY
    • computed

Follow one yuan

lens 1 of 9
After what it costs to make
102%
After running the business
-12.5%
After interest and tax
-17.8%
After what it must reinvest
28.1%
Kept after the dividend
23.9%
after what it costs to make, 102.5% of sales; after running the business, -12.5% of sales; after interest and tax, -17.8% of sales; after what it must reinvest, 28.1% of sales; kept after the dividend, 23.9% of sales

The five stops

5 of 5 read
  • After what it costs to make1,144,718,400102%
  • After running the business-139,337,836-12.5%
  • After interest and tax-198,777,200-17.8%
  • After what it must reinvest314,329,59328.1%
  • Kept after the dividend266,631,09523.9%

Of every unit of sales, 0.24 is still there after the dividend.

Of every unit of sales, 0.24 is still there after the dividend.

Every figure in this lens

Except where said otherwise: Computed from the filing for 2025

  • Sales1,117,324,092
    Source
    computed
    Statement
    income
    Fiscal year
    2025
    Reported in
    CNY
  • After what it costs to make1,144,718,400
    Source
    computed
    Statement
    income
    Fiscal year
    2025
    Reported in
    CNY
  • After running the business-139,337,836
    Source
    computed
    Statement
    income
    Fiscal year
    2025
    Reported in
    CNY
  • After interest and tax-198,777,200
    Source
    computed
    Statement
    income
    Fiscal year
    2025
    Reported in
    CNY
  • After what it must reinvest314,329,593
    Source
    computed
    Statement
    income
    Fiscal year
    2025
    Reported in
    CNY
  • Kept after the dividend266,631,095
    Source
    computed
    Statement
    income
    Fiscal year
    2025
    Reported in
    CNY

Filed figures cite the filing they come from; figures marked Market data are quotes as of the date shown. Not a recommendation and not advice.

Past figures are not a forecast. Anything we modelled is labelled as ours. You can lose money on any security.